Grail (NASDAQ:GRAL) Trading Down 4.1% - Should You Sell?

Grail, Inc. (NASDAQ:GRAL - Get Free Report)'s stock price traded down 4.1% during mid-day trading on Tuesday . The stock traded as low as $24.08 and last traded at $23.00. 280,781 shares traded hands during trading, a decline of 77% from the average session volume of 1,214,771 shares. The stock had previously closed at $23.98.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley boosted their price target on Grail from $16.00 to $20.00 and gave the stock an "equal weight" rating in a report on Tuesday, March 18th.

Grail Stock Performance

The company's 50 day moving average is $33.52 and its two-hundred day moving average is $23.20.

Grail (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($1.86) earnings per share for the quarter, beating analysts' consensus estimates of ($4.41) by $2.55. The firm had revenue of $38.25 million for the quarter, compared to analysts' expectations of $35.33 million. As a group, equities analysts predict that Grail, Inc. will post -15.15 EPS for the current fiscal year.

Insider Buying and Selling at Grail

In other Grail news, CFO Aaron Freidin sold 1,816 shares of Grail stock in a transaction on Friday, March 7th. The shares were sold at an average price of $31.20, for a total value of $56,659.20. Following the completion of the transaction, the chief financial officer now directly owns 335,170 shares of the company's stock, valued at $10,457,304. This trade represents a 0.54 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Robert P. Ragusa sold 7,625 shares of the business's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $31.21, for a total transaction of $237,976.25. Following the completion of the sale, the chief executive officer now owns 828,662 shares in the company, valued at approximately $25,862,541.02. This trade represents a 0.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,550 shares of company stock worth $360,436 in the last quarter.

Remove Ads

Institutional Investors Weigh In On Grail

Several institutional investors have recently modified their holdings of the stock. Crcm LP purchased a new stake in Grail during the 4th quarter valued at $65,061,000. Sessa Capital IM L.P. purchased a new stake in shares of Grail in the fourth quarter valued at $53,550,000. Primecap Management Co. CA bought a new stake in shares of Grail in the 4th quarter worth about $37,118,000. Baker BROS. Advisors LP purchased a new position in shares of Grail during the 4th quarter worth about $29,098,000. Finally, Vanguard Group Inc. bought a new position in Grail during the 4th quarter valued at about $25,902,000.

Grail Company Profile

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.